Clear Search sequence regions


  • case (1)
  • child (1)
  • child preschool (1)
  • children (2)
  • desmoid fibromatosis (4)
  • doxorubicin (9)
  • female (1)
  • free (3)
  • glycols (2)
  • humans (1)
  • male (1)
  • therapies (1)
  • tumor size (1)
  • Sizes of these terms reflect their relevance to your search.

    Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression-free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics. © 2016 Wiley Periodicals, Inc.

    Citation

    Prasanna Ananth, Annette Werger, Stephan Voss, Carlos Rodriguez-Galindo, Katherine A Janeway. Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatric blood & cancer. 2017 Jul;64(7)

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 27905688

    View Full Text